>>NATICK, Mass., May 22 /PRNewswire/ -- Sequitur, Inc. announced today that its agreement to provide Procter & Gamble (P&G) Pharmaceuticals (NYSE: PG - News) with access to its functional genomics technology has been renewed and expanded. Sequitur will perform biological screening and supply its proprietary antisense/RNAi compounds and methods to P& G Pharmaceuticals for use in its target validation studies as part of the multi-year agreement. The agreement has been expanded to include additional therapeutic areas.
Sequitur's proprietary functional genomics technology accelerates drug discovery by helping to identify the triggers of disease. Sequitur's technology is a tool for determining the function of the human genetic code. Antisense/RNAi can help to determine gene function and validate small molecule drug targets by specifically inhibiting gene expression. Sequitur's Functional Genomics Program offers second and third generation antisense compounds (including RNAi), collaborative research and cell transfection optimization.
Tod Woolf, Sequitur's CEO, noted, "We are gratified that our agreement with Procter & Gamble Pharmaceuticals, which is one of our largest collaborations, has been extended and expanded. This will extend our work with P&G into its third year."
Larry Games, P&G Pharmaceuticals Vice President of R&D Stated, "We have been pleased with this collaboration. Sequitur has been a good working partner, participating in a collaborative relationship and providing cutting edge technologies which allow P & G Pharmaceuticals to rapidly assess new targets in our Discovery pipeline."
Sequitur is a privately held corporation that offers products and services to modulate and detect gene expression. Sequitur also offers collaborations to develop therapeutic RNAi compounds. Sequitur's other clients include Bristol-Myers Squibb, Incyte, Amgen, GlaxoSmithKline, Pfizer, Genentech, Roche, Schering-Plough, Wyeth and others.<<
snip
Cheers, Tuck |
